Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6881420B2 · kind B2 · utility
33Cited by
37References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2001 |
| Grant date | Apr 19, 2005 |
| Priority date | — |
| Expiry date | Dec 25, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4808
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides oral dosage forms and compositions for administering antineoplastic agents, such as irinotecan, etoposide, paclitaxel, doxorubicin and vincristine, whose oral effectiveness is limited by pre-systemic and systemic deactivation in the GI tract. Gelling of the gastric retention vehicle composition, and in the case of solid forms concomitant expansion of the composition, retains the antineoplastic drug in the patient's stomach, minimizing pre-systemic and/or systemic deactivation of the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.